Twist Bioscience Stock News

Business is booming for these life science businesses, but their stock prices have been slashed to bargain-basement prices.

Twist Bioscience Corp (TWST) shares closed 0.2% lower than its previous 52 week low, giving the company a market cap of $3B. The stock is currently down 13.8% year-to-date, down 59.9% over the past 12 months, and up 376.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 32.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 146.8% The company's stock price performance over the past 12 months lags the peer average by 14.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Twist Bioscience Corp (TWST) shares closed today at 0.2% above its 52 week low of $66.61, giving the company a market cap of $3B. The stock is currently down 13.8% year-to-date, down 59.9% over the past 12 months, and up 376.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 0.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 146.8% The company's stock price performance over the past 12 months lags the peer average by 14.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

There's a clear path for these stocks to deliver 10x gains by the end of the decade.

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 25,000 shares of the businesss stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $85.20, for a total transaction of $2,130,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. William Banyai [] The post Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $2,130,000.00 in Stock appeared first on ETF Daily News .

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 25,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $85.20, for a total value of $2,130,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC []

Codiak BioSciences (NASDAQ:CDAK) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations. Insider and Institutional Ownership 62.9% of Codiak BioSciences shares are owned by institutional investors. Comparatively, 96.1% []

These stocks have been beaten down in 2021. But their prospects remain bright.

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 25,000 shares of the firms stock in a transaction on Wednesday, December 15th. The stock was sold at an average price of $85.20, for a total value of $2,130,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through []

Twist Bioscience Co. (NASDAQ:TWST) shares reached a new 52-week low during trading on Friday after an insider sold shares in the company. The stock traded as low as $74.11 and last traded at $74.11, with a volume of 2501 shares changing hands. The stock had previously closed at $89.41. Specifically, COO Patrick Weiss sold 2,801 []

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick Weiss sold 2,801 shares of the businesss stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $84.00, for a total transaction of $235,284.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through []

Shares of Twist Bioscience Co. (NASDAQ:TWST) gapped up prior to trading on Thursday . The stock had previously closed at $84.16, but opened at $89.24. Twist Bioscience shares last traded at $88.96, with a volume of 1,959 shares. TWST has been the subject of several research reports. Robert W. Baird reduced their target price on []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Sosei Group Corporation (the Company; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares. The

Environmental Impact Acquisition (NASDAQ:ENVI) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Environmental Impact Acquisition and Twist Biosciences gross revenue, earnings []

Twist Bioscience Co. (NASDAQ:TWST) CFO James M. Thorburn sold 7,000 shares of the businesss stock in a transaction dated Wednesday, December 8th. The shares were sold at an average price of $89.37, for a total value of $625,590.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available []